Most Read Articles
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).

Serum CRP, ECOG scores, treatment intensity predict survival in metastatic SCCHN

10 Jul 2017
Time from diagnosis to relapse, treatment intensity, C-reactive protein (CRP) and leukocyte levels, and Eastern Cooperative Oncology Group (ECOG) scores are independent predictors of prognosis in metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN), shows a new study.

Multivariable analysis of 128 cetuximab-treated SCCHN patients showed that a less intensive therapy was independently associated with worse overall survival (OS; hazard ratio [HR], 2.560; 95 percent CI, 1.510 to 4.341; p<0.001) than those who received polychemotherapy with cetuximab.

Similarly, high ECOG scores (HR, 2.048; 1.319 to 3.179; p=0.001), high CRP (HR, 1.651; 1.058 to 2.575; p=0.027) and leukocyte (HR, 2.224; 1.416 to 3.495; p=0.001) levels and shorter time from primary diagnosis to palliative therapy (HR, 1.830; 1.185 to 2.824; p=0.006) were independent predictors of poor prognosis.

A prognostic score for the patients was generated by assigning each of the five factors one point. Patients that had zero points had a median OS of 21.5 months.

In contrast, those with one, two, three, four and five points had median OS of 12.7, 6.8, 4.9, 0.7 and 0.6 months, respectively (p<0.001).

The median OS of patients with zero to one risk factor (13.6 months) was significantly greater than those with two to three risk factors (6.1 months; p<0.001) which, in turn, was significantly greater than those with four to five risk factors (0.7 months; p<0.001).

All participants recruited were diagnosed with metastatic or recurrent SCCHN and received either cetuximab alone or in combination with chemotherapy. Prognostic scores for OS were derived using measurements from serum samples and patient clinical characteristics.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).